FDA Sends CBD Enforcement Policy to White House: The Free Ride May Be Over
Advertisement
On March 13, 2026, the U.S. Food and Drug Administration submitted a notice titled "Cannabidiol (CBD) Products Compliance and Enforcement Policy" to the White House Office of Information and Regulatory Affairs (OIRA) for review. While the full text of the policy has not been publicly released, the filing marks the most concrete signal in years that the FDA is moving toward structured federal oversight of the sprawling CBD marketplace.
For an industry that has operated in a regulatory gray zone since the 2018 Farm Bill [Quick Definition: The federal law that legalized hemp with less than 0.3% THC, creating the hemp CBD industry] legalized hemp, this could be the beginning of the end of the free ride.
Key Takeaways
- The FDA submitted a "Cannabidiol Products Compliance and Enforcement Policy" to the White House for review on March 13, 2026 — the strongest signal yet that structured federal CBD oversight is coming.
- The policy's specifics are unknown, but it could range from targeting egregious actors to establishing comprehensive compliance frameworks for the entire CBD market.
- The timing coincides with marijuana rescheduling efforts and Farm Bill hemp restrictions, creating a convergence of regulatory activity that will reshape the cannabis industry landscape.
Table of Contents
- What We Know — and What We Don't
- Why the FDA Has Struggled with CBD
- The Size and Scope of the CBD Market
- The Rescheduling Connection
- What This Could Mean for Consumers and Businesses
- What Happens Next
What We Know — and What We Don't
The filing is listed on Reginfo.gov as a pending Executive Order 12866 regulatory review, classified as a notice rather than a formal rule. This distinction matters: a notice suggests the FDA is outlining its enforcement approach rather than proposing binding regulations that would go through the traditional rulemaking process with public comment periods.
What the notice does not reveal is the specifics. Key questions remain unanswered: Will the FDA target only the most egregious actors — products making unsubstantiated health claims, or those with dangerous contaminants? Or is this a broader compliance framework that could restructure the entire category?
Anthony Varrell, an industry analyst, described the submission as "the end of regulatory radio silence" and "the first step toward structured federal oversight." That characterization captures the significance of the moment: after years of the FDA saying it lacked the appropriate regulatory tools for CBD, the agency is finally putting pen to paper.
Why the FDA Has Struggled with CBD
The regulatory limbo around CBD products traces back to the 2018 Farm Bill, which legalized hemp and hemp-derived compounds at the federal level but did not create a clear pathway for CBD to be sold in food, beverages, or dietary supplements. The FDA maintained that because CBD was first studied as a drug (the pharmaceutical Epidiolex was approved in 2018), it could not be legally marketed as a dietary supplement or food additive under existing law.
This created a paradox: CBD products flooded the market — from tinctures and gummies to pet treats and skincare — while the FDA repeatedly stated these products were technically illegal under federal food and drug law but declined to enforce against the vast majority of them.
In January 2023, the FDA itself acknowledged that "existing regulatory frameworks for foods and dietary supplements are not appropriate for cannabidiol," effectively admitting it needed a new approach. Congress has debated various legislative solutions since then, but no comprehensive CBD regulatory bill has passed.
The March 2026 submission suggests the FDA is no longer waiting for Congress to act. Instead, the agency appears to be establishing its own enforcement priorities — a move that could bring order to a market plagued by inconsistent quality, mislabeling, and unverified health claims.
The Size and Scope of the CBD Market
The unregulated nature of the CBD market has not prevented its explosive growth. The U.S. CBD market is estimated to exceed $7 billion in annual sales, with thousands of brands competing across categories including oils, edibles, topicals, capsules, and beverages.
However, the lack of federal oversight has created real problems for consumers. Independent lab testing has repeatedly shown that many CBD products do not contain the amount of CBD listed on their labels, with some containing significantly more or less than advertised. Others have been found to contain contaminants including heavy metals, pesticides, and higher levels of THC than permitted.
A 2020 study published in the Journal of the American Medical Association found that only about 30 percent of CBD products sold online were accurately labeled. More recent analyses have shown improvement in some segments of the market, but the absence of enforceable federal standards continues to undermine consumer confidence.
For the industry itself, the regulatory vacuum has been a double-edged sword. While it has allowed rapid growth, it has also prevented legitimate CBD companies from accessing traditional banking, payment processing, and retail distribution channels that require regulatory clarity. Major retailers have been reluctant to stock CBD products without clear federal guidelines, limiting the market's potential.
The Rescheduling Connection
The FDA's CBD enforcement policy submission comes against the backdrop of a broader federal cannabis policy shift. President Trump's December 2025 executive order directed the Attorney General to complete the process of reclassifying marijuana from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] under the Controlled Substances Act. While rescheduling would not directly address the regulatory status of hemp-derived CBD products, it signals a federal government increasingly willing to engage with cannabis policy rather than avoid it.
Separately, the 2026 Farm Bill legislation advancing through Congress includes provisions that would ban intoxicating hemp [Quick Definition: Hemp-derived products engineered to produce a psychoactive high]-derived products containing more than 0.4 milligrams of THC, as well as those containing synthetic or unnatural cannabinoids. If enacted, this provision would significantly reshape the hemp derivatives market and could interact with the FDA's enforcement approach in complex ways.
For CBD companies, the convergence of rescheduling, Farm Bill restrictions, and FDA enforcement activity creates a moment of maximum uncertainty — but also potential opportunity. Companies that have invested in quality control, accurate labeling, and Good Manufacturing Practices (GMP) compliance may find themselves well-positioned if the FDA's enforcement policy rewards responsible actors while penalizing bad ones.
What This Could Mean for Consumers and Businesses
If the FDA's enforcement policy follows the pattern of its past actions in other unregulated markets, the most likely initial targets would be companies making explicit health claims — such as marketing CBD as a cure or treatment for specific diseases — without FDA approval. The agency has already issued warning letters to dozens of such companies over the past several years.
A broader enforcement framework could introduce requirements around labeling accuracy, contaminant testing, manufacturing standards, and marketing restrictions. For consumers, this would represent a significant improvement in product safety and transparency. For businesses, it could mean higher compliance costs — a burden that would fall disproportionately on smaller operators.
Industry advocates have long argued that clear regulations would actually benefit the CBD market by establishing consumer trust, enabling mainstream retail distribution, and unlocking institutional investment. The counterargument is that overly aggressive enforcement could stifle innovation and push consumers toward unregulated gray-market products.
What Happens Next
The OIRA review process typically takes 30 to 90 days, though there is no strict timeline. Once the review is complete, the FDA could publish its enforcement policy as a guidance document, which would outline the agency's priorities without creating legally binding rules. Alternatively, the agency could use the notice as a precursor to formal rulemaking — a process that would take significantly longer but produce enforceable regulations.
For the multibillion-dollar CBD industry, the waiting game continues. But the direction of travel is now clear: the era of federal non-engagement with CBD regulation is ending. What replaces it will determine the future of one of the fastest-growing consumer product categories in America.
Pull-Quote Suggestions:
"CBD market is estimated to exceed $7 billion in annual sales, with thousands of brands competing across categories including oils, edibles, topicals, capsules, and beverages."
"For the multibillion-dollar CBD industry, the waiting game continues."
"While it has allowed rapid growth, it has also prevented legitimate CBD companies from accessing traditional banking, payment processing, and retail distribution channels that require regulatory clarity."
Why It Matters: The FDA submitted a CBD compliance enforcement policy to the White House for review on March 13. Here's what it means for the multibillion-dollar CBD market.